Dialysis provider DaVita Inc. (NYSE:DVA) will be announcing earnings results tomorrow after market close. Here’s what to look for.
DaVita beat analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $3.26 billion, up 4.6% year on year. It was a slower quarter for the company, with a miss of analysts’ EPS estimates.
Is DaVita a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting DaVita’s revenue to grow 3.8% year on year to $3.27 billion, slowing from the 7.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.15 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. DaVita has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average.
Looking at DaVita’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Encompass Health delivered year-on-year revenue growth of 12.7%, beating analysts’ expectations by 1.8%, and Centene reported revenues up 3.4%, topping estimates by 4.4%. Encompass Health traded up 1.3% following the results while Centene was down 6.3%.
Read our full analysis of Encompass Health’s results here and Centene’s results here.
Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. DaVita is up 6.3% during the same time and is heading into earnings with an average analyst price target of $159.48 (compared to the current share price of $172.25).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。